I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
SB 225002 is a selective non-peptide CXCR2 inhibitor which suppresses IL-8 induced neutrophil chemotaxis and margination. In addition, SB 225002 reduces MPO activity, IL-1β, MIP-2, and keratinocyte-derived chemokine (KC) levels. Further studies suggest that SB 225002 decreases the expression of vascular endothelial growth factor, inducible NOS (NO synthase), and Cox-2 (cyclooxygenase-2 proteins) in colon tissue.
Julie Catusse; Anne Liotard; Bruno Loillier; Didier Pruneau; Jean-Luc Paquet. Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen α (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2. Biochemical Pharmacology. 2003, 65, (5), 813-821.
John R. White; Judithann M. Lee; Peter R. Young; Robert P. Hertzberg; Anthony J. Jurewicz; Margery A. Chaikin; Katherine Widdowson; James J. Foley; Lenox D. Martin; Don E. Griswold and Henry M. Sarau. Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration. The Journal of Biological Chemistry. 1998, 273, 10095-10098.
Hazard Statements: H315-H319-H335
Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.
Precautionary Statements: P260-P201-P280g-P304+P340-P405-P501a
Do not breathe dust/fume/gas/mist/vapours/spray. Obtain special instructions before use. Wear protective gloves. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.